首页> 外文期刊>Expert opinion on biological therapy >Current advances in the algae-made biopharmaceuticals field
【24h】

Current advances in the algae-made biopharmaceuticals field

机译:藻类生物制药领域的研究进展

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Introduction: The biopharmaceuticals industry demands new production platforms to address several challenges; such as cost reduction to make biologics accessible in low-income countries, safety enhancement of the product, development of products administered by noninvasive routes, and expansion of potential biosimilars and biobetters. Microalgae are emerging hosts for biopharmaceuticals production with the potential to meet such requirements. Areas covered: Nowadays successful cases on the production of vaccines, antibodies, antimicrobial peptides, growth factors/cytokines, and hormones in algae have been reported. This review comprises an updated outlook covering protein expression strategies, a compilation of functional biopharmaceuticals produced in algae, and companies investing in this technology. Expert opinion: Key perspectives for the field include optimizing yields, scaling up production and completing preclinical trials. The experience from the field of plant-made biopharmaceuticals is commented as a key reference that will aid in the development of the algae-made biopharmaceuticals field.
机译:简介:生物制药行业需要新的生产平台来应对多项挑战;例如降低成本,使生物制剂在低收入国家可及,提高产品的安全性,开发非侵入性途径给药的产品,以及扩大潜在的生物仿制药和生物改良剂。微藻是生物制药生产的新兴宿主,具有满足此类要求的潜力。涵盖领域:目前已有关于生产疫苗、抗体、抗菌肽、生长因子/细胞因子和藻类激素的成功案例的报道。本综述包括涵盖蛋白质表达策略的最新展望、藻类生产的功能性生物制药的汇编以及投资于该技术的公司。专家意见:该领域的主要观点包括优化产量、扩大生产规模和完成临床前试验。植物生物制药领域的经验被评论为有助于藻类生物制药领域发展的关键参考。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号